On August 5, 2025, the U.S. Department of Health and Human Services (HHS) announced the cancellation of 22 mRNA vaccine development projects, representing a total investment of approximately $500 million. The move marks a significant shift in federal policy regarding the funding of mRNA technology, which was central to the development of COVID-19 vaccines.

Health Secretary Robert F. Kennedy Jr., who has previously expressed skepticism toward vaccines, stated that the decision was based on internal data suggesting that these vaccines are ineffective at preventing upper respiratory infections, such as COVID-19 and the flu. This justification has become a point of contention. Critics of the decision point to existing Phase 3 trial data from manufacturers like Moderna, which indicate that the vaccines do provide protection against these infections. The discrepancy between the Secretary’s stated rationale and the published clinical trial results has drawn criticism from public health advocates who argue that the policy change ignores established scientific evidence.

The cancellation represents a broader pivot away from the mRNA platform that had been a cornerstone of federal pandemic response efforts. While the administration maintains that the funding shift is necessary based on their assessment of the technology's performance, the decision has sparked debate over the role of political leadership in directing scientific research and the interpretation of clinical data.